Senolytic Therapeutics

Improving the lives of patients affected by age-related diseases

We are Senolytic Therapeutics, a pharmaceutical company that develops novel medicines that target and eliminate damaged cells.

About SENOLYTIC THERAPEUTICS

At Senolytic Therapeutics, we develop novel classes of medicines that target and eliminate damaged (senescent) cells.

Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of those affected by diseases associated with aging.

We have developed a unique technological portfolio which is based on drug therapies that eliminate senescent in age-related diseases.

Senolytic Therapeutics is located in Boston (US) and Barcelona (Spain).

We are a member of the Life Biosciences group.

 

0101

Sen01

Our leading program SEN01 is a new senolysis targeted therapy targeting fibrotic diseases and certain cancers.

0202

Sen02

The discovery program SEN02 focuses on immune system-based elimination of damaged cells to improve patient outcomes.

0303

Sen03

The SEN03 program is a discovery platform to design novel molecules and tested in other anti-aging indications in-house or in collaboration with academic institutions.

OUR SCIENCE

Cellular senescence was first described more than 50 years ago, far preceding the conceptualization of apoptosis. For many years, cellular senescence was understood as a poorly defined cell-cycle arrest associated with organismal aging.
Today, cellular senescence is considered a variant of the apoptotic cellular suicide paradigm and, more specifically, an assisted cellular suicide.

SENESCENT CELLS

Senescent or damaged cells accumulate in tissues, accelerating aging and contributing to disease development. Recent academic work in mouse models has formally proven that accumulation of senescent cells drives the development of multiple diseases and that their elimination can be therapeutic. Therefore, pharmaceutical strategies to remove damaged or senescent cells are of fundamental interest.

our findings

Our academic founders have played a key role in demonstrating that senescence occurs in response to cellular damage and that senescence occurs in vivo in normal and pathological settings.

The science is based on our unique ability to design and develop strategies that selectively target and eliminate damaged cells from tissues where they drive disease progression.

Founders have published key academic papers in the field.

0
Peer-reviewed papers
0
publications in Nature
0
publications in Science
0
publications in Cell

THERAPEUTIC FOCUS

Our therapeutic approach is based on the clearance of damaged cells as a promising strategy to reduce chronic inflammation and to rejuvenate tissues.

Designed therapies will be efficacious in treating multiple disorders which are caused and driven by the accumulation of damaged cells. For example, in fibrotic diseases such as Idiopathic pulmonary fibrosis (IPF). Also, our molecules will be of use in eliminating cancer cells that have been pushed into senescence by approved chemotherapy and radiotherapy.

Preclinical
SEN01
Targeted drug (IPF-Cancer)

The accumulation of Cellular senescence worsens the severity of several fibrotic pathologies. The SEN01 program aims to develop senolytic compounds that target and eliminate senescent cells in fibrotic diseases and certain cancers.

DISCOVERY
SEN02
Immunotherapy (Oncology)

The discovery program SEN02 is focused on immune system-mediated clearance of damaged cells to improve post-oncological treatment.

DISCOVERY
SEN03
Discovery platform

We are in the process to discover novel senolytic compounds in collaboration with other companies and research organizations.

Quality of life
We want to improve the lives of patients affected by age-related diseases
STRATEGY
Senolysis targeted therapy & Immune system-based clearance of damaged cells
Selection
We selectively target and eliminate damaged cells
Progression
We are advancing our portfolio of therapies to clinical trials

Our Team

The concept behind our drug development program stems from pioneering discoveries in the field of senescence made by the founders who are world-class scientists. Senolytic Therapeutics is honoured to have a board of directors and advisors with a prestigious and exceptional history of launching and expanding successful ventures. The leadership team has first-rate experience in advancing scientific discoveries from early-stage into clinical trials.

Leadership Management

Dr. Marc Ramis Castelltort (CEO)

Marc co-founded Senolytic Therapeutics and serves as a CEO. He is an experienced pharmaceutical and biotechnology executive. He brings a combination of scientific experience, gained through his academic career, and a proven track record of successfully translating technologies into pharmaceutical products. Marc is also an advisor for Life Biosciences Inc. in Europe helping to scout novel aging-associated ventures. Dr. Ramis-Castelltort’s experience spans academia and the business world. He has had an impressive and wide-ranging career, from co-founding and leading pharmaceutical, academic, and venture capital firms, such as Senolytic Therapeutics, Cebiotex, TBI and Chasing Science, to working with premiere research institutions such as Cancer Research UK, Oxford University Innovation and IRB Barcelona The companies he’s built and advised have created drug-delivery nano-systems for cancer, brokered corporate-academic partnerships, and more. Dr. Ramis-Castelltort’s academic degrees include a Ph.D. in Biochemistry from the University of Oxford, a Harvard Business School PLD Program, a M.S. in Chemical Engineering and a B.S. in Chemistry from IQS in Barcelona.

Follow me on Twitter
My linkedIn
Timothy Cash (CSO)

Tim has extensive experience in aging and age-related diseases such as cancer and diabetes. He has carried out multiple genetic and drug screens to identify novel diabetes and cancer therapeutics during his academic career which has inspired him to pursue a career in industry. Tim has a Ph.D. in Cell and Molecular Biology at the University of Pennsylvania and outstanding postdoctoral experience at the prestigious Spanish National Cancer Center (CNIO) in Madrid, Spain.

Follow me on Twitter
My linkedIn
Jennifer Cermak (SVP, Development)

Jennifer has 20 years R&D experience focused on the formation, early discovery and clinical development strategy of biotechnology companies from candidate selection through Phase IV global clinical trials for drugs, biologics and devices. She is an advisor to several biotechnology start-up companies, participating in Series A through IPOs. Jennifer was part of the Sirtris Pharma’s Executive Management Team and GSK’s CEO’s Future Strategy group. She led Flex Pharma to the discovery and clinical development of its lead drug candidate and Renovia, Inc. to a clinically significant, FDA-cleared device. Jennifer gained a Ph.D. in Pathology from Boston University School of Medicine and a postdoctoral fellowship in the Department of Surgery at Harvard Medical School.

Follow me on Twitter
My linkedIn
Brian Malone (CFO)

Brian Malone is the Chief Financial Officer at Senolytic Therapeutics where he has responsibility for all financial and operational aspects of the company. He has over 30 years’ experience in financial services worldwide, having worked in Europe and the UK with the last 15 years spent in the Boston, MA. He has an honors degree in science from University College Dublin and is a Fellow of the Irish Institute of Chartered Accountants. Additionally he has postgraduate qualifications in information technology from Dublin City University and in International Financial Reporting Standards.

Follow me on Twitter
My linkedIn
Karolina Chwalek (IP Director)

Karolina has extensive experience in technology transfer, IP, strategic partnerships and business development. She is currently faculty of genetics at Harvard Medical School. Jennifer gained a PhD in regenerative medicine at Max Planck Institute, Dresden with high impact papers and a postdoctoral research fellow at Tufts University.

Follow me on Twitter
My linkedIn

Board of Directors

Lawrence Gozlan

Lawrence is appointed as a Chairman of the board of directors. Mr. Gozlan, a leading biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. The Company was founded to provide high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry.Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte. During 2014, Mr. Gozlan was a Director of ASX-listed companies OncoSil Medical Limited (ASX:OSL) and Phosphagenics Limited (ASX:POH). He retired from these appointments in May 2015. Mr. Gozlan is currently a non-executive director of AusBiotech, which is the Australian Biotechnology Industry body. He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne specializing in neurodegenerative diseases.

Follow me on Twitter
My linkedIn
Tristan Edwards

Tristan is a Hedge fund manager with over 16 years experience in Australia, London, HK and Singapore (GSAM, Brevan Howard, Trafalgar Capital, Mosaic Asset Management). He was the Founder and Chief Investment Officer of Mosaic Asset Management, an Asian based equities hedge fund with $100m AUM committed pre launch. Tristan has extensive trading of listed equities, sub underwriting, equity capital market transactions and venture capital investments. Also, he has strong knowledge of Cayman fund structures, the Singapore regulatory authority (MAS), and compliance & operations requirements for investment vehicle. Tristan gained a Bachelor of Commerce, CFA, CMT, CPA.

Follow me on Twitter
My linkedIn
David Sinclair

David is a Tenured Professor of genetics at Harvard Medical School. He is in the Time Magazine 100 Most Influential People (2014) with seminal contributions to ageing research through discovery of role of sirtuins in ageing. David is a leading biotech entrepreneur, previous companies include Sirtris (acquired by GSK for $720M, 2008), Genocea (market cap $120M), Ovascience (market cap $280M), CohBar (market cap $85M), Metrobiotech ($50M series A), Arc-Bio ($25M series A), Liberty Biosecurity ($25M series A).

Follow me on Twitter
My linkedIn
Marc Ramis Castelltort

Marc co-founded Senolytic Therapeutics and serves as a CEO. He is an experienced pharmaceutical and biotechnology executive. He brings a combination of scientific experience, gained through his academic career, and a proven track record of successfully translating technologies into pharmaceutical products. Marc is also an advisor for Life Biosciences Inc. in Europe helping to scout novel aging-associated ventures. Dr. Ramis-Castelltort’s experience spans academia and the business world. He has had an impressive and wide-ranging career, from co-founding and leading pharmaceutical, academic, and venture capital firms, such as Senolytic Therapeutics, Cebiotex, TBI and Chasing Science, to working with premiere research institutions such as Cancer Research UK, Oxford University Innovation and IRB Barcelona The companies he’s built and advised have created drug-delivery nano-systems for cancer, brokered corporate-academic partnerships, and more. Dr. Ramis-Castelltort’s academic degrees include a Ph.D. in Biochemistry from the University of Oxford, a Harvard Business School PLD Program, a M.S. in Chemical Engineering and a B.S. in Chemistry from IQS in Barcelona.

Follow me on Twitter
My linkedIn

Scientific Founders and Advisors

Dr. Manuel Serrano

Dr. Manuel Serrano is group leader of the Cellular Plasticity and Disease laboratory at IRB Barcelona and a co-founder at Senolytic Therapeutics. Previously, Manuel was a principal investigator at the Spanish National Cancer Research Centre (CNIO), in Madrid, and Director of the Molecular Oncology Program of the CNIO. After completing his studies and PhD in Madrid, M.S. joined the laboratory of David Beach, at Cold Spring Harbor Laboratory, NY, USA, as postdoctoral fellow from 1992 to 1996. During this time, M.S. made one of his most important contributions with the discovery of the tumor suppressor p16. In 1997, M.S. established his research group in Madrid. The main contributions of the Serrano´s laboratory are related to the concept of oncogene-induced senescence and the anti-aging activity of tumor suppressors. More recently, Serrano´s group has worked on the relevance of tumor suppressors during reprogramming, and it has demonstrated the feasibility of embryonic reprogramming within live adult organisms.

Follow me on Twitter
My linkedIn
Dr. Ramón Martínez Máñez

Dr. Ramón Martínez-Máñez is full Professor of Inorganic Chemistry at the Department of Chemistry of the Polytechnic University of Valencia (UPV) and Head of the Interuniversitary Research Institute of Molecular Recognition and Technologic Development (IDM) of Valencia, Spain. Ramón is a co-founder at Senolytic Therapeutics. He is currently the Scientific Director of the Biomedical Research Center Network in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). He is an active researcher in the fields of chemical sensing and gated materials for controlled drug delivery. He has published more than 370 scientific papers in top international journals and holds 21 patents. He has been a visiting researcher at the University of Cambridge, UK. Recently he became Co-chairman of the journal ChemistryOpen and member of the International Advisory Board of the journals Chem. Asian. J. and ChemPlusChem published by Wiley-VCH.

Follow me on Twitter
My linkedIn
Dr. Joserra Murguia

Dr. Jose Ramon Murguia is Professor of Biomedicine at the Department of Biotechnology of the Technological University of Valencia (UPV) and staff scientist of the Research Center of Molecular Recognition and Technologic Development (IDM) of Valencia, Spain. Joserra is also a co-founder at Senolytic Therapeutics. He is an active researcher in the field of molecular pharmacology, and currently is deeply interested in exploring the interface between hybrid organic-inorganic nanostructured gated materials and biological systems (cells, tissues and animal models). He has published 47 scientific papers in top International Journals and holds 4 patents. He has been a visiting researcher (1997-2000) at the Clare Hall Labs, (Cancer Research UK). He has been evaluator for the Startup Grants of the European Research Council (2006-2013). Finally he has served as a referee of several top scientific journals in the fields of Biochemistry, Molecular Biology and Biomedicine

Follow me on Twitter
My linkedIn
Dr. David Sinclair

David is a Tenured Professor of genetics at Harvard Medical School. He is in the Time Magazine 100 Most Influential People (2014) with seminal contributions to ageing research through discovery of role of sirtuins in ageing. David is a leading biotech entrepreneur, previous companies include Sirtris (acquired by GSK for $720M, 2008), Genocea (market cap $120M), Ovascience (market cap $280M), CohBar (market cap $85M), Metrobiotech ($50M series A), Arc-Bio ($25M series A), Liberty Biosecurity ($25M series A).

Follow me on Twitter
My linkedIn
Dr. Nir Barzilai

Nir is the Founding director and professor, Institute for Aging Research, Albert Einstein College of Medicine. He is highly regarded for studies of the genetics of aging in long-lived Ashkenazi Jews. Nir is the Leader of the TAME trial, the world’s first drug intervention clinical trial to extend lifespan in humans. He is a Professor of medicine (endocrinology) at the Einstein College of Medicine, New York and Co-founder of CohBar Inc, a biotech company developing mitochondrial peptides for diabetes.

Follow me on Twitter
My linkedIn
Dr. Lindsay Wu

Lindsay is the RD Wright Biomedical Fellow, NHMRC Australia Senior Lecturer, Laboratory for Ageing Research. He is an UNSW Expert in metabolic biochemistry and ageing. He gained aPhD from Garvan Institute of Medical Research with influential publications. Previous companies include Intravital ($16M series A), Metrobiotech ($50M series A), Liberty Biosecurity ($25M series A).

Follow me on Twitter
My linkedIn
Dr. John Amatruda

John is a Former executive at Merck Pharmaceuticals and Bayer Corporation. He is Highly regarded for overseeing the chemical discovery, evaluation, clinical trial and FDA approval of the DPP-IV inhibitor Sitagliptin (brand name Januvia), $6B annual revenue. He also oversaw clinical trials and FDA approval for Janumet, the Januvia/metformin combination pill. He was Professor of Medicine at Yale University. Medically qualified, still in part-time clinical practice as an endocrinologist. Over 150 peer reviewed publications in endocrinology and diabetes research.

Follow me on Twitter
My linkedIn

Subscribe

Sign up with your email address to receive news and updates.

DO. OR DO NOT. THERE IS NO TRY.

Yoda

Contact Us

To learn more about our programs or inquire about working together, contact us at:


The Heritage on the Garden 75 Park Plaza Boston MA 02116-4128
natalia.molner@senolytx.com
(+34)-607046707

EU OFFICE


Barcelona Science Park; Calle Baldiri Reixac 4-8 08028 Barcelona
natalia.molner@senolytx.com
(+34)-607046707

Say Hello!